Novoheart Founder & CEO Dr. Ronald Li honored with 2017 Distinguished Alumnus Award by the University of Waterloo

Calgary, Alberta, CANADA

VANCOUVER, British Columbia, April 12, 2018 (GLOBE NEWSWIRE) -- Novoheart (“Novoheart” or the “Company”) (TSXV:NVH) (FWB:3NH) is pleased to announce that Dr. Ronald Li, Founder and CEO of the Company, has been awarded with the 2017 Distinguished Alumnus Award by the University of Waterloo, Canada, from which he graduated with a B.Sc. in 1994. As one of two recipients of the award from the Faculty of Science, Dr. Li is recognized for his two decades of research on human cardiac tissue engineering, and his continuous efforts to translate and commercialize basic findings into tangible applications and community benefits, including the founding of Novoheart in 2014.

“It is a great honor to receive this award from the University of Waterloo,” said Dr. Li. “Translating decades of research for commercialization by Novoheart has been a highly rewarding experience, and I look forward to leading the Company to realize the immense potential of our technologies to revolutionize modern medicine, and benefit patients, pharmaceutical and biotech clients, and shareholders in the process.”

For more information about the awards, please refer to the following link: 

About Novoheart:

Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics. Also known as 'human heart-in-a-jar', Novoheart’s bio-artificial human heart constructs are created using state-of-the-art and proprietary stem cell and bioengineering approaches and are utilized by drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.

For further information, please contact:
Ronald Li, CEO

Babak Pedram, Investor Relations
Virtus Advisory Group
Tel: 416-995-8651

For media enquiries or interviews, please contact:
Josh Stanbury, Media Relations
Tel. 416-628-7441

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements
Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation; statements about the Company’s future plans, its goals and expectations, and the potential applications of its MyHeartTM platform are forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the management discussion and analysis section of Novoheart Holdings Inc.’s interim and most recent annual financial statement or other reports and filings with the TSX Venture Exchange and applicable Canadian securities regulators. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.